STMN.SW Straumann (SIX) pre-market +5.69% to CHF80.56: target CHF95.42 may be tested

STMN.SW stock jumped 5.69% in pre-market trading on 25 Mar 2026 to CHF80.56, driven by a volume spike to 822,733 shares. The move makes Straumann Holding AG (STMN.SW) one of the Swiss SIX top gainers this morning in the Healthcare sector. We highlight valuation, catalysts and technical levels ahead of the next earnings date and include Meyka AI market context from our AI-powered market analysis platform.

STMN.SW stock pre-market jump and intraday picture

Straumann (STMN.SW) opened pre-market at CHF77.42 and touched CHF81.66 with a day low of CHF77.34. Volume of 822,733 vs average 400,716 implies a relative volume of 2.05, signalling outsized interest.

The immediate support sits near CHF77.34 and the next resistance cluster is the 50-day average at CHF92.35 and the 200-day average at CHF95.41.

Drivers and STMN.SW stock news that matter

The short-term lift appears driven by sector flows into Healthcare and catch-up buying after a multi-month pullback. Straumann’s product mix in implants, clear aligners and digital dentistry keeps revenue visibility higher than many peers.

Investors should watch upcoming earnings on 29 Apr 2026 and regional sales updates. For market context see reports on Investing.com source and a regional quote page source.

Valuation and STMN.SW stock financials

Straumann trades at PE 36.13 with EPS of 2.23 and market cap CHF12.85B. Price-to-sales is 4.93 and price-to-book is 5.90, above Healthcare averages, indicating a premium for growth and margins.

Key metrics include free cash flow yield 2.56%, return on equity 16.90%, current ratio 2.21, and dividend per share CHF0.95. These figures explain investor appetite despite a higher PE.

Technical outlook, indicators and Meyka grade

Momentum indicators show RSI 37.60 and MACD slightly negative, signalling short-term weakness but room for a rebound. Bollinger bands are mid CHF84.21 and lower CHF74.02, so CHF74.02 is a tactical downside reference.

Meyka AI rates STMN.SW with a score out of 100: 76.44 / B+ (BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Price targets, forecasts and STMN.SW stock outlook

Meyka AI’s forecast model projects monthly CHF61.82, quarterly CHF69.37 and yearly CHF95.42. Versus the current price CHF80.56, the yearly forecast implies an upside of 18.44% while the monthly projection implies a downside of -23.29%.

Analyst-style price-scenario: conservative CHF70.00, base CHF95.00, bull CHF110.00. These reflect near-term volatility and longer-term recovery toward mid-cycle valuation.

Risks, sector context and trading notes

Primary risks are weaker procedure volumes, FX exposure, and high valuation sensitivity if growth slows. Straumann’s PE is higher than the Healthcare sector average PE 29.73, which raises downside risk in a macro slowdown.

Traders should monitor liquidity (shares outstanding 159,450,805) and the earnings announcement on 29 Apr 2026 before taking a new position.

Final Thoughts

STMN.SW stock is a pre-market top gainer on 25 Mar 2026 after a 5.69% move to CHF80.56 and a volume surge to 822,733. Fundamentals show solid margins and cash conversion, but valuation at PE 36.13 is above sector averages and warrants caution. Meyka AI’s forecast model projects a yearly level of CHF95.42, implying an upside of 18.44% from today’s price; short-term model points are lower, with monthly CHF61.82 and quarterly CHF69.37, reflecting potential near-term volatility. Our view: watch earnings on 29 Apr 2026 and use tiered entries with stop-loss below CHF74.00 for risk control. Meyka AI provides this analysis as an AI-powered market analysis platform; forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.